These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37863168)

  • 1. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
    Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X
    Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
    Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
    Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
    Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
    Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
    Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
    Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
    Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
    Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
    Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CASP1 is a target for combination therapy in pancreatic cancer.
    Wang X; Chen Z; Nie D; Zeng X; Zhong M; Liu X; Zhong S; Wang L; Liao Z; Chen C; Li Y; Zeng C
    Eur J Pharmacol; 2023 Dec; 961():176175. PubMed ID: 37949157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
    Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
    Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
    Dai S; Peng Y; Zhu Y; Xu D; Zhu F; Xu W; Chen Q; Zhu X; Liu T; Hou C; Wu J; Miao Y
    Biomed Pharmacother; 2020 Jan; 121():109521. PubMed ID: 31689601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2.
    Cui J; Guo Y; Yin T; Gou S; Xiong J; Liang X; Lu C; Peng T
    Biomed Pharmacother; 2023 Oct; 166():115359. PubMed ID: 37639742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
    Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
    Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K/AKT signaling pathway.
    Xu C; Ye Q; Ye C; Liu S
    Biol Direct; 2023 Mar; 18(1):14. PubMed ID: 36991449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
    Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
    Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
    Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
    Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
    Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells.
    Xu C; Yu Y; Ding F
    Oncol Rep; 2018 Jul; 40(1):395-404. PubMed ID: 29781033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway.
    Lin C; Wang Y; Dong Y; Lai S; Wang L; Weng S; Zhang X
    Biol Direct; 2022 Nov; 17(1):33. PubMed ID: 36397058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.